한빛사 논문
Mirja Rotinen 1,10, Sungyong You 1,10, Julie Yang1, Simon G. Coetzee 2, Mariana Reis-Sobreiro1, Wen-Chin Huang 1,9, Fangjin Huang1, Xinlei Pan 3, Alberto Yáñez4, Dennis J. Hazelett2, Chia-Yi Chu5, Kenneth Steadman1, Colm M. Morrissey6, Peter S. Nelson7, Eva Corey6, Leland W. K. Chung5, Stephen J. Freedland1, Dolores Di Vizio1, Isla P. Garraway8, Ramachandran Murali3, Beatrice S. Knudsen1 and Michael R. Freeman 1,*
1Division of Cancer Biology and Therapeutics, Departments of Surgery & Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 2The Center for Bioinformatics and Functional Genomics, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 3Division of Immunology, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 4Board of Governors Regenerative Medicine Institute and Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 5Uro-Oncology Research Program, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 6Department of Urology, University of Washington, Seattle, WA, USA. 7Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 8Department of Urology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles , Los Angeles, CA, USA. 9Present address: Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan. 10These authors contributed equally: Mirja Rotinen, Sungyong You.
*Corresponding author
Abstract
Treatment of prostate cancer (PC) by androgen suppression promotes the emergence of aggressive variants that are androgen receptor (AR) independent. Here we identify the transcription factor ONECUT2 (OC2) as a master regulator of AR networks in metastatic castration-resistant prostate cancer (mCRPC). OC2 acts as a survival factor in mCRPC models, suppresses the AR transcriptional program by direct regulation of AR target genes and the AR licensing factor FOXA1, and activates genes associated with neural differentiation and progression to lethal disease. OC2 appears active in a substantial subset of human prostate adenocarcinoma and neuroendocrine tumors. Inhibition of OC2 by a newly identified small molecule suppresses metastasis in mice. These findings suggest that OC2 displaces AR-dependent growth and survival mechanisms in many cases where AR remains expressed, but where its activity is bypassed. OC2 is also a potential drug target in the metastatic phase of aggressive PC.
논문정보
관련 링크
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기